Search

Displaying results 7811 - 7820 of 10000 in total
  1. Drug

    Amolimogene bepiplasmid

    go.drugbank.com/drugs/DB04904
    Investigational

    Amolimogene was biologically engineered as a targeted therapy for the treatment of cervical dysplasia. … Amolimogene is an investigational therapeutic designed to specifically augment the body's defensive response to human papillomavirus (HPV).

  2. Drug

    XP21279

    go.drugbank.com/drugs/DB06319
    Investigational

    XP21279 is a prodrug of [Levodopa], a dopamine precursor used in the management of Parkinson's disease. … XP21279 was under investigation in clinical trial NCT00914602 (An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects), administered in combination with [Carbidopa

  3. Drug

    GR270773

    go.drugbank.com/drugs/DB06427
    Investigational

    NCT00089986 (completed with results, treatment of suspected or confirmed gram-negative severe sepsis in adults, comparing GR270773 with a placebo). … GR270773, was investigated in two clinical trials for its potential to treat sepsis: NCT00158769 (completed, comparing the effects of infusion between healthy adults and those with damaged livers) and

  4. Drug

    Tegoprazan

    go.drugbank.com/drugs/DB16690
    Investigational

    [A234215, A234220] Tegoprazan’s strong and sustained effect is due to its ability to be slowly cleared from the gastric glands and exertion of effects independent of acid levels. … [A234215, A234220] This drug is a potent and high-selective potassium-competitive acid blocker (P-CAB) with a fast onset of action and the ability to control gastric pH for a prolonged period of time.

    Synonyms: IN-A001
  5. Drug

    Theralizumab

    go.drugbank.com/drugs/DB15717
    Investigational

    After the first human trial, it was withdrawn due to severe toxicity (likely due to lymphopenia and human cytokine release).[A216527,A216532]

  6. Drug

    ONT-093

    go.drugbank.com/drugs/DB14069
    Experimental

    In pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations with no effect on paclitaxel pharmacokinetics. … ONT-093 is an orally bioavailable inhibitor of P-glycoprotein (P-gp).

  7. Drug

    LY2275796

    go.drugbank.com/drugs/DB05165
    Investigational

    LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that drive tumor progression, angiogenesis and metastases.

  8. Drug

    Polistes fuscatus venom protein

    go.drugbank.com/drugs/DB10959
    Approved

    Polistes fuscatus venom protein is an extract of Polistes fuscatus venom. Polistes fuscatus venom protein is used in allergenic testing.

  9. Drug

    Polistes metricus venom protein

    go.drugbank.com/drugs/DB11029
    Approved

    Polistes metricus venom protein is an extract of Polistes metricus venom. Polistes metricus venom protein is used in allergenic testing.

  10. Drug

    Vespula squamosa venom protein

    go.drugbank.com/drugs/DB11032
    Approved

    Vespula squamosa venom protein is an extract of Vespula squamosa venom. Vespula squamosa venom protein is used in allergenic testing.